Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer.
Furuya K, Nakajima M, Tsunedomi R, Nakagami Y, Xu M, Matsui H, Tokumitsu Y, Shindo Y, Watanabe Y, Tomochika S, Maeda N, Iida M, Suzuki N, Takeda S, Hazama S, Ioka T, Hoshii Y, Ueno T, Nagano H. Furuya K, et al. Among authors: maeda n. BMC Cancer. 2024 Feb 2;24(1):165. doi: 10.1186/s12885-024-11924-4. BMC Cancer. 2024. PMID: 38308214 Free PMC article.
Serum LOX-1 is a novel prognostic biomarker of colorectal cancer.
Nakashima-Nakasuga C, Hazama S, Suzuki N, Nakagami Y, Xu M, Yoshida S, Tomochika S, Fujiwara N, Matsukuma S, Matsui H, Tokumitsu Y, Kanekiyo S, Shindo Y, Maeda N, Tsunedomi R, Iida M, Takeda S, Yoshino S, Ueno T, Hamamoto Y, Ogihara H, Hoshii Y, Nagano H. Nakashima-Nakasuga C, et al. Among authors: maeda n. Int J Clin Oncol. 2020 Jul;25(7):1308-1317. doi: 10.1007/s10147-020-01673-2. Epub 2020 Apr 11. Int J Clin Oncol. 2020. PMID: 32277394
Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer.
Hazama S, Takenouchi H, Tsunedomi R, Iida M, Suzuki N, Iizuka N, Inoue Y, Sakamoto K, Nakao M, Shindo Y, Kanekiyo S, Tokumitsu Y, Yoshimura K, Maeda N, Maeda K, Maeda Y, Matsui H, Yoshino S, Nakamura Y, Fujita Y, Hamamoto Y, Okamoto M, Fujita T, Kawakami Y, Oka M. Hazama S, et al. Among authors: maeda k, maeda n, maeda y. Anticancer Res. 2014 Aug;34(8):4201-5. Anticancer Res. 2014. PMID: 25075047
Calreticulin is highly expressed in pancreatic cancer stem-like cells.
Matsukuma S, Yoshimura K, Ueno T, Oga A, Inoue M, Watanabe Y, Kuramasu A, Fuse M, Tsunedomi R, Nagaoka S, Eguchi H, Matsui H, Shindo Y, Maeda N, Tokuhisa Y, Kawano R, Furuya-Kondo T, Itoh H, Yoshino S, Hazama S, Oka M, Nagano H. Matsukuma S, et al. Among authors: maeda n. Cancer Sci. 2016 Nov;107(11):1599-1609. doi: 10.1111/cas.13061. Epub 2016 Nov 4. Cancer Sci. 2016. PMID: 27561105 Free PMC article.
A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
Yamamoto S, Maeda N, Nagashima Y, Kubo H, Sato Y, Matsui H, Inoue Y, Shindo Y, Kanekiyo S, Sakamoto K, Suzuki N, Takeda S, Ueno T, Yoshino S, Hazama S, Oka M, Nagano H. Yamamoto S, et al. Among authors: maeda n. Breast Cancer. 2017 Nov;24(6):783-789. doi: 10.1007/s12282-017-0779-7. Epub 2017 Apr 24. Breast Cancer. 2017. PMID: 28439763 Clinical Trial.
Expression levels of UL16 binding protein 1 and natural killer group 2 member D affect overall survival in patients with gastric cancer following gastrectomy.
Kamei R, Yoshimura K, Yoshino S, Inoue M, Asao T, Fuse M, Wada S, Kuramasu A, Furuya-Kondo T, Oga A, Iizuka N, Suzuki N, Maeda N, Watanabe Y, Matsukuma S, Iida M, Takeda S, Ueno T, Yamamoto N, Fukagawa T, Katai H, Sasaki H, Hazama S, Oka M, Nagano H. Kamei R, et al. Among authors: maeda n. Oncol Lett. 2018 Jan;15(1):747-754. doi: 10.3892/ol.2017.7354. Epub 2017 Nov 6. Oncol Lett. 2018. PMID: 29391893 Free PMC article.
High secreted protein acidic and rich in cysteine expression in peritumoral fibroblasts predicts better prognosis in patients with resectable gastric cancer.
Nakajima M, Yoshino S, Kanekiyo S, Maeda N, Sakamoto K, Tsunedomi R, Suzuki N, Takeda S, Yamamoto S, Hazama S, Hoshii Y, Oga A, Itoh H, Ueno T, Nagano H. Nakajima M, et al. Among authors: maeda n. Oncol Lett. 2018 Jan;15(1):803-812. doi: 10.3892/ol.2017.7418. Epub 2017 Nov 15. Oncol Lett. 2018. PMID: 29403557 Free PMC article.
Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients.
Maeda N, Yoshimura K, Yamamoto S, Kuramasu A, Inoue M, Suzuki N, Watanabe Y, Maeda Y, Kamei R, Tsunedomi R, Shindo Y, Inui M, Tamada K, Yoshino S, Hazama S, Oka M. Maeda N, et al. Among authors: maeda y. Ann Surg Oncol. 2014 Dec;21 Suppl 4(Suppl 4):S546-54. doi: 10.1245/s10434-014-3564-2. Epub 2014 Feb 22. Ann Surg Oncol. 2014. PMID: 24562936 Free PMC article.
2,162 results